What's Happening?
Thermo Fisher Scientific has introduced the Gibco CTS DynaXS Single Use Bioreactor, a platform designed to support cell therapy manufacturing. This bioreactor enables controlled, cGMP-ready cell expansion from development through commercialization. It
is part of Thermo Fisher's Cell Therapy Systems portfolio and addresses the need for scalable manufacturing solutions in the cell therapy industry. The bioreactor supports a wide range of operating conditions, allowing for efficient scale-up from small process development to large commercial runs.
Why It's Important?
The launch of the Gibco CTS DynaXS Bioreactor is significant for the cell therapy industry, which is experiencing rapid growth and increasing demand for scalable manufacturing solutions. As cell therapies expand into new therapeutic areas, manufacturers require robust platforms that ensure consistent quality and regulatory compliance. Thermo Fisher's bioreactor addresses these needs, facilitating the transition from clinical development to commercial production. This innovation supports the broader goal of making cell therapies more accessible to patients, ultimately advancing the field of regenerative medicine.
